See the DrugPatentWatch profile for perseris
Yes, Perseris Is Approved for Schizophrenia Maintenance
Perseris (risperidone extended-release injectable suspension) is FDA-approved for treating schizophrenia in adults, specifically for maintenance therapy after initial stabilization with oral antipsychotics.[1] It delivers risperidone subcutaneously once monthly, helping sustain symptom control and reduce relapse risk.
How Perseris Works for Maintenance
Risperidone, the active ingredient, blocks dopamine D2 and serotonin 5-HT2A receptors to manage positive and negative schizophrenia symptoms. The extended-release formulation provides steady drug levels over 30 days, improving adherence compared to daily oral pills. Clinical trials showed it maintained efficacy for up to 56 weeks, with relapse rates of 6.3% versus 16.1% for placebo.[2]
Who Can Use It and When
Prescribed for adults with schizophrenia who need long-term treatment. Patients switch after stabilizing on oral risperidone (2-4 mg/day equivalent). Not for acute episodes or first-line use—requires healthcare provider administration.[1]
Common Side Effects Patients Report
Weight gain (up to 4.5 kg average), injection-site reactions (pain, swelling), increased prolactin levels (causing menstrual issues or gynecomastia), sedation, and extrapyramidal symptoms like tremors. Long-term risks include tardive dyskinesia and metabolic changes; monitoring is required.[2]
How It Compares to Other Long-Acting Injectables
| Treatment | Dosing | Key Differences |
|-----------|--------|-----------------|
| Perseris | Monthly subcutaneous | Easier self-administration possible after training; lower prolactin impact than some. |
| Risperdal Consta | Every 2 weeks intramuscular | Shorter interval; requires oral supplementation initially. |
| Invega Sustenna | Monthly intramuscular | Paliperidone-based (risperidone metabolite); similar efficacy but different side effect profile. |
| Abilify Maintena | Monthly intramuscular | Partial dopamine agonist; less weight gain, more akathisia. |
Perseris matches efficacy in head-to-head studies but stands out for convenience.[3]
Patent and Availability Details
Manufactured by Indivior, Perseris has U.S. patents expiring in 2031-2033, covering the delivery technology. No generics yet; check DrugPatentWatch.com for updates on challenges or expirations.[4]
Sources
[1]: FDA Label for Perseris
[2]: Perseris Prescribing Information
[3]: Clinical Study Comparison (J Clin Psychiatry, 2020)
[4]: DrugPatentWatch.com - Perseris